LEANNE WAKSMAN: Open Payments
NPI 1275089377 · HYANNIS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,625 in 61 payments from 13 companies in 2025. Trend: 2023 $903 · 2024 $2,338 · 2025 $1,625
Food & beverage: $1,625
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $460 |
| Janssen Biotech, Inc. | 7 | $406 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $190 |
| Aimmune Therapeutics, Inc. | 7 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $87 |
| Ardelyx, Inc. | 4 | $82 |
| Phathom Pharmaceuticals, Inc. | 3 | $70 |
| Ferring Pharmaceuticals Inc. | 2 | $48 |
| GENZYME CORPORATION | 1 | $24 |
| Braintree Laboratories, Inc. | 1 | $24 |
Products named: TREMFYA, XIFAXAN, ZENPEP, RINVOQ, ENTYVIO, IBSRELA, SKYRIZI, LINZESS.
Industry payments across MA — which companies pay providers there.
